Please select the option that best describes you:
How do you approach treatment of 1p19q non-codeleted high grade gliomas?
Has the recently published interim analysis of the CATNON trial altered your utilization of temozolomide?
Does IDH status change your treatment approach?
Answer from: Radiation Oncologist at Academic Institution
The question focuses on the management of 1p19q non-codeleted high-grade gliomas, which for all practical purposes translates roughly to the entity that by legacy terminology has been referred to as anaplastic astrocytoma. This question has come into focus with the recent publication of results of t...
Sign in or Register to read more